Analyst Stock Ratings: Golden Minerals Company (AUMN), ASLAN Pharmaceuticals Limited (ASLN)

Golden Minerals Company (NYSE:AUMN) tinted loss of -1.51% (-0.01 points) to US$0.29. The volume of 0.13 Million shares climbed down over an trading activity of 216.21 Million shares. EPS ratio determined by looking at last 12 month figures is -0.03. Over the same time span, the stock marked US$0.47 as its best level and the lowest price reached was US$0.19. The corporation has a market cap of US$27.23 Million.

Golden Minerals Company (NYSE:AUMN)’s earnings per share has been growing at a 0 percent rate over the past 5 year when average revenue increase was noted as -7.5 percent. The return on equity ratio or ROE stands at 0 percent while most common profitability ratio return on investment (ROI) was -26 percent. The company’s institutional ownership is monitored at 46.8 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 68.3 percent gross margin.

Daily Analyst Recommendations

A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 0 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 0 think it is Hold. Recently, analysts have updated the overall rating to 2. 1 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.

ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) is worth US$701.89 Million and has recently risen 17.11% to US$4.38. The latest exchange of 0.06 Million shares is below its average trading activity of 26.96 Million shares. The day began at US$0 but the price moved to US$0 at one point during the trading and finally capitulating to a session high of US$0. The stock tapped a 52-week high of US$10.44 while the mean 12-month price target for the shares is US$7.38.

Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 16.78, and a price to sales ratio of 0. For the past 5 years, the company’s revenue has grown 0%, while the company’s earnings per share has grown 0%. With an institutional ownership near 9.35%, it carries an earnings per share ratio of -0.32.